Leigh is an EIR at Atlas and CSO at Pheon Therapeutics. Prior to joining Atlas, Leigh was a CSO at Cullinan Oncology and an Executive Partner with MPM Capital. He previously held leadership roles with Pfizer and Merck and began his career at the Novartis Institutes for Biomedical Research. Leigh is an Oncology expert with more than 20 years of experience developing targeted therapies. He holds a Ph.D in Biochemistry from Rutgers University.